更新于：2024-12-22
Droperidol
氟哌利多
更新于：2024-12-22
概要
基本信息
药物类型 小分子化药 |
别名 1-(1-(3-(p-fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone、1-(1-(4-(p-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone、1-{1-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one + [12] |
作用机制 D2 receptor拮抗剂(多巴胺D2受体拮抗剂) |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1970-06-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C22H22FN3O2 |
InChIKeyRMEDXOLNCUSCGS-UHFFFAOYSA-N |
CAS号548-73-2 |
关联
35
项与 氟哌利多 相关的临床试验Low-Dose Droperidol and Its Association with QTc Interval Changes in Emergency Department Patients
Comparison of the effects of ginger, ondansetron and droperidol on nausea and vomiting after hysterectomy
Low-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery: A Randomized, Double-blind, Placebo-controlled Trial
100 项与 氟哌利多 相关的临床结果
登录后查看更多信息
100 项与 氟哌利多 相关的转化医学
登录后查看更多信息
100 项与 氟哌利多 相关的专利（医药）
登录后查看更多信息
2,424
项与 氟哌利多 相关的文献（医药）2025-02-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Agitation: Neurobiology and current management guidelines
Review
作者: Van Remmen, Sarah ; Mahmood, Sara ; Rullo, Mario ; Miller, Christopher W T
There have been important updates in the guidelines for the management of agitation in emergency room settings, including psychiatric emergency services. This manuscript provides a synthesis of current recommendations, combined with a detailed breakdown of the neurobiology of agitation, linking these neuroscientific dimensions with the pharmacological profiles of the drugs recommended by practice guidelines (as well as the profiles of other important agents). Since Project BETA (Best Practices in Evaluation and Treatment of Agitation) guidelines were published in 2012 (by the American Association for Emergency Psychiatry), there have been several developments in the standard of care, including an increase in use of ketamine and droperidol. Recommended treatment strategies for clinicians will be presented, including consideration of how to address specific causes of agitation.
2025-01-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Comparing the cardiorespiratory safety of parenteral olanzapine and benzodiazepines to parenteral haloperidol/droperidol and benzodiazepines in emergency department patients
Article
作者: Miller, Christopher D ; Meola, Gregory ; Miller, Christopher D. ; Darko, William ; Bradley, Katherine ; Feldman, Elizabeth A. ; Seabury, Robert ; Feldman, Elizabeth A ; Schrader, Joshua
INTRODUCTION:
This study sought to assess the cardiorespiratory safety of parenteral olanzapine and benzodiazepine combination treatment compared to parenteral droperidol or haloperidol and benzodiazepine combination treatment.
MATERIALS AND METHODS:
This was a retrospective chart review conducted in adult emergency department patients who received intramuscular (IM) or intravenous (IV) droperidol, haloperidol, or olanzapine within one hour of IM or IV benzodiazepine. Patients were stratified into groups based on whether they received either olanzapine in combination with a benzodiazepine (n = 48) or droperidol or haloperidol in combination with a benzodiazepine (n = 48).
RESULTS:
Patients in each group had a decrease in their systolic blood pressure (SBP) after IM/IV olanzapine and IM/IV droperidol or haloperidol when used in combination with an IM/IV benzodiazepine ((Olanzapine + benzodiazepine (mmHg), median (IQR): Pre-SBP: 132 (117-151) vs. Post-SBP: 117 (99-131), p < 0.01) (Droperidol or haloperidol + benzodiazepine (mmHg), median (IQR): Pre-SBP: 138 (122-149) vs. Post-SBP: 106 (98-127), p < 0.01)). Both groups had similar percent SBP decreases post-combination treatment (Olanzapine + benzodiazepine (15.6 %) vs. Droperidol or haloperidol + benzodiazepine (15.2 %); p = 0.55). We did not observe any statistically significant between group differences for hypotension (Olanzapine + benzodiazepine: 1/48, 2.1 % vs. Droperidol or haloperidol + benzodiazepine: 3/48, 6.3 %; p = 0.62)), escalation in oxygen requirements (Olanzapine + benzodiazepine: 7/48, 14.6 %) vs. Droperidol or haloperidol + benzodiazepine: 5/48, 10.4 %; p = 0.76)), or intubation due to cardiorespiratory depression (Olanzapine + benzodiazepine: 0/0, 0 % vs. Droperidol or haloperidol + benzodiazepine: 0/0, 0 %; p = 1.00)).
CONCLUSION:
This study found decreases in SBP after administering parenteral olanzapine and parenteral droperidol or haloperidol in combination with a parenteral benzodiazepine. The percent change in SBP and the frequency of hypotensive episodes post-combination treatment were not different between groups. There were also no differences between groups in need of increased oxygen requirements post-combination treatment or need for intubation due to cardiorespiratory depression. This study suggests parenteral olanzapine in combination with a parenteral benzodiazepine may have comparable cardiorespiratory safety versus parenteral droperidol or haloperidol in combination with a parenteral benzodiazepine when treating agitation in the adult ED.
2024-12-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Droperidol use in emergency patients with abdominal pain, nausea, and vomiting requires further analysis
Letter
作者: Pruc, Michal ; Swieczkowski, Damian ; Szarpak, Lukasz
100 项与 氟哌利多 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 1989-01-01 | |
| 麻醉 | 日本 | 1971-05-10 | |
| 恶心和呕吐 | 美国 | 1970-06-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 322 | DEX, OND, and placebo | 鏇衊繭鬱鏇艱夢構壓淵(糧鑰艱構鹽壓構衊鬱膚) = 築選蓋鹽艱鹽廠構網膚 繭鏇遞淵遞襯築窪憲廠 (觸艱獵醖願獵構鏇鏇繭 ) | - | 2017-06-01 | ||
DEX, OND, and DRO | 鏇衊繭鬱鏇艱夢構壓淵(糧鑰艱構鹽壓構衊鬱膚) = 鑰鹹顧襯築積餘鹹顧淵 繭鏇遞淵遞襯築窪憲廠 (觸艱獵醖願獵構鏇鏇繭 ) | ||||||
N/A | - | 選膚顧簾顧淵蓋夢簾廠(憲遞醖蓋窪糧構築築鏇) = 憲選觸齋夢鹽鏇築壓構 鏇簾窪鑰願範齋衊鬱願 (憲獵淵廠鑰構醖鬱糧顧 ) | - | 1991-01-01 | |||
Droperidol + placebo pretreatment | 獵壓鹹餘蓋簾製觸膚夢(鹽膚積壓襯網膚蓋鹹鏇) = 憲顧醖觸範蓋窪鬱繭壓 齋襯繭積選鏇範遞衊糧 (繭鬱獵廠衊網築範鏇獵 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用